Modality
Degrader
MOA
TROP-2 ADC
Target
CDK2
Pathway
Ferroptosis
GA
Development Pipeline
Preclinical
~Jul 2022
→ ~Oct 2023
Phase 1
~Jan 2024
→ ~Apr 2025
Phase 2
Jul 2025
→ Mar 2027
Phase 2Current
NCT05333371
1,707 pts·GA
2025-07→2027-03·Recruiting
1,707 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-1111mo awayPh3 Readout· GA
Trial Timeline
Q3Q42026Q2Q3Q42027
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-03-11 · 11mo away
GA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05333371 | Phase 2/3 | GA | Recruiting | 1707 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 |